DOCSLIB.ORG

Rudy Dekeyser: Alumnus on a Mission for Better Science VIB Research May Lead to Effective Alzheimer's Therapies Big Entrances

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Rudy Dekeyser: Alumnus on a Mission for Better Science VIB Research May Lead to Effective Alzheimer's Therapies Big Entrances QUARTERLY NEWSLETTER OF VIB. VIBTIMES DECEMBER 2016 20 Years VIB: science meets life Rudy Dekeyser: alumnus on a VIB research may lead to Big entrances and mission for better science effective Alzheimer’s therapies venerable exits 20 YEARS VIB 20 years of VIB: achieving excellence and maintaining it 4 Excellence in scientific research as one of the spearheads for creating a strong Flemish economy In 20 years of VIB, we have come a tremendous way. When we kicked off 6 Going beyond borders to take VIB research to new heights in 1996, nobody would have dared to suspect that our achievements would 8 Science meets life be internationally acclaimed as they are today. And although the research 12 Rudy Dekeyser: alumnus on a mission for better science institutes that served as VIB’s foundations already enjoyed worldwide 14 Shaping the future at VIB’s second postdoc event fame at the time, it is clear that VIB has been – and still is – a strong 16 VIB Alumni Award 2017: now accepting nominations catalyst to ensuring that the huge potential of biotechnological research 17 Basic research: where curiosity leads to groundbreaking innovation in Flanders thrives. 18 Structural biology elevates basic research to a higher plane 20 Sharing resources is at the ‘core’ of excellent science When our founding fathers Jo Bury and Rudy Dekeyser undertook the 22 Stimulating international diversity to drive excellent science mammoth task of putting Flanders on the global biotech map, they set 23 VIB’s PhD scholarships: three recent international hits up a board of directors consisting of several delegations representing On roots & wings: breeding a generation of scientists at VIB government, universities and industry. I belonged to the latter as the CEO of 24 Janssen Pharmaceutica, which gave me a front seat in witnessing how VIB’s 26 VIB scarf basic research could contribute over the years to a gradual yet massive 27 Twitter wall #20yrsVIB change in our pharmaceutical and medical landscape. This contribution is, as we all know, one of VIB’s strong points. And the urgency to add societal value will only increase. If we take a look at today’s global challenges, SCIENCE our added value lies in three domains: medical innovations to improve 28 Plant peptides: keys to understanding plant growth healthcare, plant science for sustainable food production, and industrial and stress responses applications that can strengthen our economic fabric. 29 VIB papers get a popularity boost: highly-cited works on the rise 30 Maize team To further accelerate the valorization of scientific insights, VIB has set up 31 VIB research may lead to effective Alzheimer’s therapies close collaborations that fall into two distinct categories. On the one hand, 32 Ghent-based researchers are the cream of the crop we are joining forces with other Flemish and international research groups in rheumatology to share technological and scientific expertise – after all, collaborations 34 Diverse VIB team investigates the possibilities of plant proteins are the key to great scientific breakthroughs. On the other hand, our Tech 36 The synapse series: how Patrik Verstreken’s basic research Transfer team is proactively reaching out to corporate partners to establish advances multiple fields industry collaborations. In some cases, VIB is even the cradle of new spins- 38 Three steps add up to one substantial leap in cancer offs. Further on in this issue of VIBnews, you will read about a few fine metabolism research examples of recent research that has been taken to the next level. 40 How our Switch Lab plans to catch tumors in a spider’s web But even with the greatest ambitions and waterproof strategic plans, 42 Quickscan excellent science always starts on a personal level. Ideas are conceived by the brains of creative individuals with relentless determination. But execution always requires teamwork – preferably when heterogeneous TECHNOLOGY perspectives and expertise are brought to the table. I think that VIB has 44 Tech Watch: single cell technologies found a great model in which its complementary departments and teams operate and report. This diversity, of which I’m an ardent advocate, is also reflected in the dozens of nationalities at VIB. On page 26, you will read BUSINESS more about our international recruiting programs – and how they lead to 45 AgroSavfe’s designer proteins for crop protection prove their worth unique insights. 46 VIB Tech transfer takes research to private partners and beyond Speaking of VIB’s foreign researchers, they naturally find themselves immersed in our typical Flemish habits and mindsets after a while. And PEOPLE no doubt it must have struck them that we are quite a humble people. We 48 Big entrances and venerable exits at VIB don’t really like showoffs. But in my own (humble) opinion, we can take 52 Awards en grants great pride in our achievements. We are playing at the top of the league here, which is why we should also set the bar high, publicly express our ambitions and claim the necessary resources. After all, that is the only way STAF VAN REET we can maintain excellence in research and valorization. EVENTS The former CEO and Head of R&D Janssen Pharmaceutica, is 55 Picture report 20 years VIB now managing director of Viziphar Biosciences, a consultancy 56 VIB Biotech Tour and support company in the life sciences sector. Staf Van Reet serves as an industry delegate in the VIB board of directors. 58 VIB Conferences: Revolutionizing Next-Generation Sequencing 60 Calender Minister Muyters, how did you still. We may be at the top now, but overseas to bring specialized get to know VIB? it takes continuous effort to stay knowledge to Flanders if needed. “I first came into contact with VIB there. That involves making hard during my days at the Social and choices about individual research A second challenge is to further Economic Council of Flanders (SERV) lines while paying close attention refine the expertise of knowledge and later as Managing Director to new interdisciplinary fields. We workers after they’ve graduated. of VOKA, the Flemish Chamber also have to find ways to further Again, I see an enormous advan- of Commerce. Of course, I got to reduce the risks of basic research. If tage in the close proximity of our know the institute a lot better when we really pave the way and prepare educational centers and research I joined the Flemish government optimally for technology transfer, it institutions. There is always a high in 2009. What remained constant is likely to generate more value. As probability that a specific speciali- during all those years is the image of a result, investing in a professional zation or postgraduate program is a very dynamic and internationally- team of tech transfer specialists offered somewhere in Flanders. competitive organization.” is essential.” I firmly believe in VIB’s strategic When VIB was founded in 1995, the Do you think Discovery Sciences, plan for the future which should translation of academic knowledge VIB’s strategic initiative that aims enable the institute to contribute into tangible benefits for society was to increase the success rate of even more to society. I’m therefore lagging behind in Flanders. How far translational research, will play a big pleased that, together with the have we come since then? part in this de-risking? entire Flemish Government, I can “I think Flanders should be proud “Discovery sciences is a great announce a substantial rise in the Philippe Muyters of what its research institutions concept. Given the extremely annual grant for VIB which will allow have achieved in recent decades. long development phases for new them to implement some new The concentration of knowledge in therapies, talking to interested initiatives described in a small but central region, where parties requires perfect preparation their strategy.” several universities and research and real data that has been gathered institutes are less than a hundred through clinical testing or breeding kilometers apart, clearly gives us experiments. I’m convinced that an enormous advantage. Having Discovery Sciences will contribute to EXCELLENCE IN SCIENTIFIC such a strong biotech cluster not the translation of basic research into only puts Flanders on the map for potential applications.” international high-tech companies, RESEARCH AS ONE OF THE it also offers an attractive habitat for A knowledge economy also needs I firmly believe in top scientists.” specialized knowledge workers. What are the challenges in this area? VIB’s strategic Is Flanders ahead of the pack when “For several years now, we have SPEARHEADS FOR CREATING A it comes to combining basic research been encouraging students to plan for the future with technology transfer? enroll in studies in the areas of “There is definitely a lot of interest science, technology, engineering and which should enable in the VIB model abroad. Some mathematics (STEM). An investment STRONG FLEMISH ECONOMY countries are wondering how they we absolutely need to continue. the institute to can launch a similar institute, so On the other hand, life sciences we’ve definitely hit upon a good is a very international field, which contribute even The Flanders coalition agreement of 2014-2019 states that Flanders should be one of the top five European regions by 2020. formula. However, we can’t forget means that our research institutions This target acts as a compass for the policy of Philippe Muyters, Flemish Minister for Work, Economy, Innovation and Sports. that other countries are not standing and companies should also recruit more to society. 20 Years VIB 5 VIB’S 8 THEMATICAL RESEARCH CENTERS GOING BEYOND BORDERS TO TAKE VIB RESEARCH TO NEW HEIGHTS Jo Bury and Johan Cardoen Since it was established over two decades ago, VIB has dedicated itself to groundbreaking basic research in life sciences.
Load more

Recommended publications
  • 05C Imec En.Pdf
    ic process technologies process industry solutions industry power electronics power spectrum sensing body area networks hyp euv lithography ERS cognitive radio p IMEC NUMBERS E ct A CHALLENGE FOR EACH TALENT collaboration R al i sustainable mobility M wireless communication wireless efficient communication aging 1,850 660 imec academy Imec is a multidisciplinary environment. To accomplish our research we welcome electronic engineers, smart systems electromechanic engineers, chemists, physicists, material scientists, bio engineers, computer scientists... More than 1,850 people work at imec, 35% of 660 European universities and research centers joint R&D which are guest researchers and residents from get training and access to advanced knowledge Imec also welcomes industrially oriented engineers and people with even other backgrounds to support the academic and industrial world. and tools from imec. organic electronics worldwide imec’s development activitiesThe and ime cooporateC C withampus industry, universities, polytechnic schools, associated partnerships photovoltaics labs, and other research institutes. 37 66 300mm 37 is the average age of our staff. biomedical66 nationalities work at imec. To stay on the forefront of research on The imec campus also houses laboratories electronics future cleanroom nanotechnology and nanoelectronics, imec for solar cell research, research on sustain- disposes of an ultramodern research facil- able wireless communication, biomedical imeC vision systems 450mm compatible ity that is continuously expanding. The imec research and long-term brain research in your future 208 285 campus comprises 30,481m² office space, the framework of NERF. aT a glanCe nanoparticles READY TOsmall laboratories, APPLY training facilities and ? starts at imec technical and IT support rooms.
    [Show full text]
  • An Open Source Physical Layer for the DARPA Spectrum Collaboration Challenge
    electronics Article SCATTER PHY: An Open Source Physical Layer for the DARPA Spectrum Collaboration Challenge Felipe A. P. de Figueiredo 1,2,* , Dragoslav Stojadinovic 3, Prasanthi Maddala 3, Ruben Mennes 4, Irfan Jabandži´c 1 , Xianjun Jiao 1 and Ingrid Moerman 1 1 IDLab, Department of Information Technology at Ghent University—IMEC, 9052 Ghent, Belgium; [email protected] (I.J.); [email protected] (X.J.); [email protected] (I.M.) 2 Instituto Nacional de Telecomunicações—INATEL, 37540-000 Santa Rita do Sapucaí, MG, Brazil 3 WINLAB, Rutgers University, New Brunswick, NJ 08901, USA; [email protected] (D.S.); [email protected] (P.M.) 4 Department of Mathematics and Computer Science, University of Antwerp—iMinds, 2000 Antwerp, Belgium; [email protected] * Correspondence: [email protected] Received: 12 October 2019; Accepted: 11 November 2019; Published: 14 November 2019 Abstract: DARPA, the Defense Advanced Research Projects Agency from the United States, has started the Spectrum Collaboration Challenge with the aim to encourage research and development of coexistence and collaboration techniques of heterogeneous networks in the same wireless spectrum bands. Team SCATTER has been participating in the challenge since its beginning, back in 2016. SCATTER’s open-source software defined physical layer (SCATTER PHY) has been developed as a standalone application, with the ability to communicate with higher layers through a set of well defined messages (created with Google’s Protocol buffers) and that exchanged over a ZeroMQ bus. This approach allows upper layers to access it remotely or locally and change all parameters in real time through the control messages.
    [Show full text]
  • Biomérieux and Biocartis Sign Strategic Partnership in Molecular Diagnostics
    bioMérieux and Biocartis Sign Strategic Partnership in Molecular Diagnostics Co-development of assays and co-distribution of a fully integrated molecular platform due for launch in 2012 bioMérieux gains exclusive rights in microbiology bioMérieux takes equity stake in Biocartis Marcy l’Etoile (France) and Lausanne (Switzerland) – November 4, 2010 — bioMérieux and Biocartis announced today that they have entered into a strategic agreement to co-develop assays on Biocartis’ fully integrated molecular diagnostics system, which the two companies will co-distribute starting in 2012. Under the agreement, bioMérieux will have worldwide exclusive rights to develop and commercialize microbiology assays on the platform. It will also have access to the platform for certain oncology and theranostics assays. bioMérieux has taken a €9 million equity stake in Biocartis. Biocartis has continued to successfully develop its molecular diagnostics platform, which was acquired from Philips earlier this year. The platform now fully integrates all the steps of a multiplexed molecular assay, from sample-in to data- out, in a sealed disposable cartridge, which avoids any contamination risk. Providing rapid results, the system is able to perform complex tests on a wide variety of samples, including oncology assays on tissue. The Biocartis platform does not require molecular biology experience or infrastructure with highly skilled technicians, and involves only 1-2 minutes hands-on time. Adapted to both small and large labs, the platform is fully scalable and allows random access use. bioMérieux, the world leader in microbiology, will enhance the Biocartis platform’s broad menu with an exclusive line of tests for healthcare-associated infections and sepsis.
    [Show full text]
  • Invitation to Annual Shareholders' Meeting
    PRESS RELEASE REGULATED INFORMATION 10 April 2018, 07:00 CEST Invitation to Annual Shareholders’ Meeting Biocartis to propose new board composition Mechelen, Belgium, 10 April 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), has the honor to invite its shareholders, warrant holders, directors and statutory auditor to its annual shareholders' meeting that will be held on Friday 11 May 2018 at 2:00 p.m. CEST (‘AGM’) at the offices of the Company at Generaal de Wittelaan 11B, 2800 Mechelen, Belgium. The agenda of the AGM includes the proposal for a new board composition based on the appointment of five new independent board members and the re-appointment of three board members whose current mandates will expire at the closing of the AGM. The proposed board composition will allow for a transition towards a board of directors consisting predominantly of independent directors. Subject to the AGM approving the proposed resolutions, the board of directors will be composed as follows as from the closing of the AGM: Five new independent board members: CRBA Management BVBA, represented by Christian Reinaudo (candidate chairman of the board), Ann-Christine Sundell, Harry Glorikian, CLSCO BVBA, represented by Leo Steenbergen, and Luc Gijsens BVBA, represented by Luc Gijsens. Additional information on the proposed new board candidates is included in the explanatory note prepared by the board of directors which can be found on the Company’s website. Four existing board members: Herman Verrelst (CEO) and the re-appointment of three board members, i.e. Peter Piot (independent director), Hilde Windels BVBA, represented by Hilde Windels (non-executive director) and Roald Borré (non-executive director).
    [Show full text]
  • Praesens Foundation, Institut Pasteur, Institut Pasteur De Dakar, University of Nebraska Medical Center, Twist Bioscience Consortium Win Prix Galien Medstartup Award
    Praesens Foundation, Institut Pasteur, Institut Pasteur de Dakar, University of Nebraska Medical Center, Twist Bioscience Consortium Win Prix Galien MedStartUp Award October 24, 2019 -- Consortium Developed an Integrated Solution for Better Preparedness and Faster Response to Outbreaks and Epidemics in High-Risk Areas -- BRUSSELS & PARIS & SOUTH SAN FRANCISCO, Calif. & OMAHA, Neb.--(BUSINESS WIRE)--Oct. 24, 2019-- The Praesens Foundation, the Institut Pasteur, the Institut Pasteur de Dakar, University of Nebraska Medical Center and Twist Bioscience Corporation (NASDAQ: TWST) today announced that the consortium is the winner of the Prix Galien MedStartUp award in the category: 'Best Collaboration Dedicated to the Developing or Underserved Populations Worldwide'. The consortium works together to develop, quantify and scale up a range of innovative solutions on the continent of Africa to ensure better preparedness and response to infectious disease outbreaks. This includes assays to rapidly identify pathogens developed for and by low and middle income countries that are not necessarily addressed by the traditional diagnostic players and will benefit the communities that need it most. “Past and recent disease outbreaks of Ebola, SARS, MERS-CoV, Zika and Dengue, have shown that infectious diseases continue to affect many lives while also representing social, economic, and national security threats that can quickly evolve into global health crises1, causing major human suffering and imposing enormous economic damage,” said Dr. Rudi Pauwels,
    [Show full text]
  • Meeting Report: 26Th International Conference on Antiviral Research Q
    Antiviral Research 100 (2013) 276–285 Contents lists available at ScienceDirect Antiviral Research journal homepage: www.elsevier.com/locate/antiviral Review Meeting report: 26th International Conference on Antiviral Research q R. Anthony Vere Hodge Vere Hodge Antivirals Ltd, Old Denshott, Leigh, Reigate, Surrey, UK article info abstract Article history: The 26th International Conference on Antiviral Research (ICAR) was held in San Francisco, California from Received 2 August 2013 May 11 to 15, 2013. This article summarizes the principal invited lectures at the meeting. The opening Accepted 8 August 2013 symposium on the legacy of the late Antonín Holy´ included presentations on his pioneering work with Available online 21 August 2013 nucleotide analogs, which led to the development of several antiviral drugs including tenofovir. This drug has transformed the treatment of HIV infection and has recently become the first-line therapy for chronic Keywords: hepatitis B. The Gertrude Elion Award lecturer described the anti-HIV activities of the CCR5 inhibitor Human immunodeficiency virus cenicriviroc and the reverse transcriptase inhibitor festinavirÒ, and also reviewed the evaluation of bio- Hepatitis B degradable nanoparticles with adjuvant activity. The William Prusoff Award winner reported on the cre- Hepatitis C Herpesviruses ation of NAOMI, a computer model with 21 enzymes to predict the activity of nucleoside analogs against Antiviral therapy hepatitis C virus (HCV). Other invited lecturers discussed the development of countermeasures against severe dengue and the potential of RNA virus capping and repair enzymes as drug targets. Topics in the clinical symposium included the current status of the anti-HCV compounds sovaprevir, ACH-3102, miravirsen and ALS-2200; the evaluation of single-tablet regimens for HIV infection; and the investiga- tion of cytomegalovirus resistance to CMX001.
    [Show full text]
  • Johnson & Johnson to Acquire Tibotec-Virco
    Johnson & Johnson to Acquire Tibotec-Virco NEW BRUNSWICK, N.J., March 22 /PRNewswire-FirstCall/ -- Johnson & Johnson today announced it has signed a definitive agreement to acquire all of the assets of Tibotec-Virco NV, a privately-held biopharmaceutical company focused on developing anti-viral treatments, with several promising compounds in development for the treatment of infectious diseases including HIV. The transaction is valued at approximately $320 million in cash and debt. Johnson & Johnson is expected to incur a one-time charge of approximately $145 million, or $0.05 per share, upon closing, reflecting the write-off of in-process research and development costs. The transaction is anticipated to close in the second quarter of 2002 subject to customary closing conditions and regulatory approvals. Excluding one-time charges, the acquisition is not expected to impact earnings for 2002 or 2003. "Tibotec-Virco will provide a good strategic fit with our current pharmaceutical research and development operations," said Dr. Per Peterson, Chairman, Research & Development for the pharmaceuticals group of Johnson & Johnson. "By combining Tibotec-Virco's expertise with our own research and development activities, we will expand our drug discovery and development capabilities, particularly in the field of anti-viral therapies." Headquartered in Mechelen, Belgium, Tibotec-Virco applies the latest techniques in ultra-high throughput screening, pharmacogenomics, molecular biology and artificial intelligence to discovering and developing new drugs. The company has drug discovery and development programs focusing on potential new drugs that are active against drug-resistant strains of HIV including two products in early clinical development. Tibotec-Virco also has early stage research programs concentrating on the development of treatments for hepatitis C and other infectious diseases.
    [Show full text]
  • Life Sciences 2010.Key
    LIFE SCIENCES FLANDERS Prof. Dr. Ann Van Gysel, Managing Director FlandersBio FLANDERS, BELGIUM Centrally Located Biotech hub SUCCESSFUL BIOTECH HUB • World renowned research centers, universities and hospitals • 143 life sciences companies with biotech activities • 118 conduct innovative R&D • Flanders ranks no 2 in Europe • Total market cap, stock listed biotech companies • Flanders Ranks no 1in Europe • Annual life sciences convention >900 participants LIFE SCIENCES AREAS • Medical Biotech - focus on healthcare, from diagnostics to therapeutics • Plant Biotech - largest R&D hub in Europe, from molecular breeding to GMOs • Industrial Biotech - focus on bioprocessing, from enzymes to biofuels and food STRONG IN R&D • Innovative research • Strong life sciences companies network • Big in Biopharma • Clinical excellence INNOVATIVE RESEARCH • High quality universities • Excellent research institutes, focus on life sciences • VIB [world class biotech research] • IMEC [focus on nanotechnology] • CMI [translational medicine] Ind. Products Health care Agro & Food R&D provider Tech provider 143 BIOTECH COMPANIES 12 24 21 15 64 Ind. Products Health care Agro & Food R&D provider 13.000 Tech provider EMPLOYEES IN 384 R&D 1.163212 >30.000 in total 4.648 6.652 BELGIUM, HOME TO ... • Pharmaceutical companies • 5% of the top-100 drugs are developed in Belgium • Per capita the highest number of drugs in development • Total production: 5.2 billion euro • Total export value: 34 billion euro source: pharma.be CLINICAL EXCELLENCE • Dense medical network •
    [Show full text]
  • Resistance Analyses in HIV Infected Patients with a History of Multiple
    Sex Transm Inf 2001;77:449–452 449 Sex Transm Infect: first published as 10.1136/sti.77.6.449 on 1 December 2001. Downloaded from Resistance analyses in HIV infected patients with Original a history of multiple antiretroviral treatment article regimens Andreas Plettenberg, Dirk Albrecht, Thore Lorenzen, Volker Paech, Heiko Petersen, Thomas Fenner, Thomas Meyer, Rüdiger Arndt, Kurt Hertogs, Rudi Pauwels, Thomas Weitzel, Albrecht Stoehr Objective: To assess HIV-1 isolate based resistance profiles from extensively pretreated patients and eVects of a resistance guided switch of antiretroviral therapy. Methods: In a prospective study phenotypic and genotypic resistance analyses were performed on HIV infected individuals with failure of the current therapy and history of at least three anti- retroviral regimens. Antiretroviral therapy was changed according to the results. Viral load and CD4 lymphocyte counts were measured at baseline, after 10 (SD 2), and 24 (2) weeks. Results: All patients (n=52) failed their actual regimen. Currently versus ever previously taking the specific drug, resistance associated mutations and phenotypic resistance to AZT and 3TC were found in over 80% of individuals; resistance to DDI and D4T was detected in less than 10% of cases. A resistance guided switch of therapy was followed by a median decrease of viral load of 0.5 log10 units after 24 weeks. Individuals resistant to two or more drugs compared with patients with resistance to less than two drugs of ongoing treatment, were switched to a regimen contain- ing DDI, D4T, and a PI or NNRTI. After 10 (SD 2) weeks viral load decrease was pronounced in patients with resistance to at least two drugs in the previous regimen.
    [Show full text]
  • Corporate Presentation
    CORPORATE PRESENTATION PUBLIC IMEC’S MISSION IMEC’S MISSION Imec is the world-leading R&D and innovation hub in nanoelectronics and digital technology. IMEC’S MISSION As a trusted partner for companies, start-ups and academia we bring together brilliant minds from all over the world in a creative and stimulating environment. IMEC’S MISSION By leveraging our world-class infrastructure and local and global ecosystem of diverse expert partners across a multitude of industries, we accelerate progress towards a connected, sustainable future. CLOSE TO 3,500 HIGHLY SKILLED RESEARCHERS € >500M 2016: 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 1986 1985 REVENUE 1984 74 DIFFERENT NATIONALITIES 250 184 115 107 101 96 76 53 35 39 30 34 22 25 12 11 13 15 13 7 9 6 6 10 7 7 8 6 1 2 2 4 1 2 1 1 1 5 1 2 2 1 5 1 1 1 1 2 3 5 2 4 5 3 1 5 1 3 5 1 1 4 1 5 2 1 3 3 1 2 3 2 2 1 3 Iran Iraq Italy Italy Peru Peru USA India Japan Japan Spain Israel Israel Brazil China Nepal Poland Poland France Turkey Turkey Tunisia Tunisia Taiwan Taiwan United Ireland Ireland Algeria Estonia Austria Finland Senegal Cyprus Cyprus Mexico Greece Greece Canada Uganda Croatia Croatia Belgium Slovakia Slovakia Swedish Swedish Pakistan Ukraine Georgia Slovenia Slovenia Norway Norway Malaysia Malaysia Vietnam Portugal Portugal Egyptian Hungary Lebanon Nigerian Armenia Moldova Moldova Romania Romania Australia Lithuania Bulgarian Morocco Morocco Germany Germany Denmark Indonesia Colombia Singapore Singapore Argentinia Philippines Cameroon Cameroon Costa Rica Dominican Bangladesh Bangladesh Nicaraguan Hong Kong Hong Kong Switzerland South Africa South Russian Fed.
    [Show full text]
  • Janssen Diagnostics and Biocartis Announce Launch of Influenza-Respiratory Virus Panel on the Idylla™ Platform
    PRESS RELEASE Janssen Diagnostics and Biocartis announce launch of Influenza-Respiratory Virus Panel on the Idylla™ platform Mechelen and Beerse, Belgium, 30 November 2015 - Janssen Diagnostics, part of the Johnson & Johnson family of companies (NYSE: JNJ) and Biocartis (Euronext Brussels: BCART), an innovative molecular diagnostics company, today announced the launch of their first infectious disease test on the Idylla™ platform. The Idylla™ Respiratory IFV-RSV Panel has been developed by Janssen Diagnostics and is intended for the detection of various strains of Influenza Virus (IFV) and Respiratory Syncytial Virus (RSV). The Idylla™ Respiratory IFV-RSV Panel received CE-IVD marking on 18 November 2015 and is being launched for commercial use in Europe and other geographies recognising the CE-mark. Janssen Diagnostics has appointed Biocartis as co-exclusive worldwide distributor of the test. Respiratory viruses are one of the most important causes of morbidity and mortality throughout the world1 with the influenza virus killing at least 50 million and up to 100 million people in the last century alone2. The majority of diagnostic tests currently used for this market are rapid immunoassays which are chosen due to their low cost and convenience. However, one of the key downsides of these rapid tests is their poor sensitivity. Negative samples are typically re-tested in a central lab with a more sensitive molecular test, delaying time-to-result by many hours. The new Idylla™ Respiratory IFV-RSV Panel, running on the Idylla™ platform, combines in one single product the speed of rapid tests with the quality and sensitivity standards of central lab tests.
    [Show full text]
  • IMEC Inaugurates New Nanoelectronics Laboratory 8 May 2004
    IMEC inaugurates new nanoelectronics laboratory 8 May 2004 Leuven, Belgium, May 7, 2004 – IMEC today competitiveness of Flanders, Belgium and Europe inaugurated its new nanoelectronics laboratory. by further developing high-tech know-how and will IMEC used the celebration to announce a new serve as a unique place where experts from core research partner in its sub-45nm research research institutes, semiconductor companies, platform, and excellent financial results for its fiscal material and equipment suppliers around the world year 2003. IMEC again succeeded in achieving an will jointly tackle the increasing technological increase in revenue, proving IMEC’s sound growth complexities of the nanoelectronics era." dynamics since its founding in 1984. Today’s announcements illustrate the success of IMEC’s Original press release can be found at business model to globally tackle the increasing www.imec.be intellectual and financial complexities of technology. The new nanoelectronics research facility will enable IMEC to maintain its world-leading role in research in nano-scaled technologies. Started under construction in early 2003, the facility represents a total investment of 84 million euro. Of that total, 37.2 million euro represents a grant from the local government, and the remaining 46.8 million was obtained as a loan, financially supported by the European Investment Bank ( EIB ), from Fortis Bank. Situated adjacent to the existing IMEC campus, the new facility includes a three-level fabrication (ie, fab) structure, as well as an office accommodations for more than 400 people and a central utility building. The fab has a total work surface of 16,280 m2 and includes a plenum, a 3,200 m2 ball room-style cleanroom, with 2,200 m2 of space sitting on a vibration-controlled waffle table, a clean subfab and a utility fab.
    [Show full text]